Endogenous Interleukin-11 (IL-11) Expression Is Increased and Prophylactic Use of Exogenous IL-11 Enhances Platelet Recovery and Improves Survival During Thrombocytopenia Associated With Experimental Group B Streptococcal Sepsis in Neonatal Rats

ABSTRACT Future preventive and/or concurrent therapy of neonatal sepsis may require the use of adjuvant immunohematopoietic therapy. In the present study, using reverse transcription-polymerase chain reaction, we demonstrated a significant increase in IL-11 mRNA extracted from the femurs of group B...

Full description

Saved in:
Bibliographic Details
Published in:Blood cells, molecules, & diseases molecules, & diseases, 1996, Vol.22 (1), p.57-67
Main Authors: Chang, Mei, Williams, Angela, Ishizawa, Lori, Knoppel, Annika, van de Ven, Carmella, Cairo, Mitchell S.
Format: Article
Language:English
Subjects:
Animals
Gene Expression
Interleukin-11 - genetics
Interleukin-11 - metabolism
Interleukin-11 - pharmacology
Platelet Count
Rats
Rats, Sprague-Dawley
Recombinant Proteins - genetics
Recombinant Proteins - pharmacology
Sepsis - blood
Sepsis - complications
Sepsis - prevention & control
Streptococcal Infections - blood
Streptococcal Infections - complications
Streptococcal Infections - prevention & control
Streptococcus agalactiae
Thrombocytopenia - blood
Thrombocytopenia - complications
Thrombocytopenia - prevention & control
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT Future preventive and/or concurrent therapy of neonatal sepsis may require the use of adjuvant immunohematopoietic therapy. In the present study, using reverse transcription-polymerase chain reaction, we demonstrated a significant increase in IL-11 mRNA extracted from the femurs of group B streptococcus (GBS)-infected rats during acute thrombocytopenia (platelet count: 65.8 ± 19.3 K/mm 3, n=5) compared to that of uninfected neonatal rats (NR) (635.2 ± 89 K/mm 3, n=5) (174 ± 17% vs. 100%, p
ISSN:1079-9796
1096-0961
DOI:10.1006/bcmd.1996.0009